# Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial

## TL;DR

A study found that using an app to monitor symptoms helped younger women stick to their breast cancer treatment better than usual care.

## Contribution

App-based remote monitoring improved adherence to endocrine therapy specifically in premenopausal women.

## Key findings

- App-only monitoring increased 12-month adherence in premenopausal women to 53.9% compared to 25.0% in usual care.
- No improvement in adherence was observed for postmenopausal women using the app.
- Remote monitoring may help reduce adherence gaps in younger breast cancer patients.

## Abstract

Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9% vs. EUC: 25.0%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.